1/52
Comprehensive practice flashcards covering pathophysiology, diagnostic criteria, biomarker analysis, evidence-based pharmacology, reperfusion pathways, and nursing care for Acute Coronary Syndrome (ACS).
Acute Coronary Syndrome (ACS)
A spectrum of conditions encompassing ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), and unstable angina (UA), caused by unstable atheromatous plaque rupture or endothelial disruption with transient or permanent thrombotic occlusion of coronary arteries.

Coronary Arteries (Heart Vascular Supply)
The arterial branches supplying oxygenated blood to the myocardium, predominantly comprising the Left Coronary Artery, Left Anterior Descending (LAD) artery, Left Circumflex artery, and Right Coronary Artery (RCA).
ST-Elevation Myocardial Infarction (STEMI)
An acute transmural myocardial necrosis caused by complete coronary artery occlusion, diagnosed by persistent (>20minutes) ST-segment elevation in ≥2 contiguous leads or new-onset left bundle-branch block (LBBB).

Non-ST-Elevation Acute Coronary Syndrome (NSTEACS)
An acute coronary syndrome entity encompassing NSTEMI and unstable angina, typically reflecting subendocardial ischaemia or partial vessel occlusion presenting with ST-segment depression, T-wave inversion, or normal ECGs.
Unstable Angina (UA)
Myocardial ischaemia at rest or with minimal exertion in the absence of acute cardiomyocyte necrosis, demonstrating normal serial cardiac biomarkers (troponin) and variable ECG changes.
Type 1 Myocardial Infarction
Spontaneous myocardial infarction related to atherosclerotic plaque rupture, ulceration, fissuring, erosion, or dissection with resulting intraluminal thrombus in one or more coronary arteries leading to decreased myocardial blood flow and myocyte necrosis.
Type 2 Myocardial Infarction
Myocardial necrosis resulting from a condition other than coronary artery disease that causes an imbalance between myocardial oxygen supply and demand (e.g., tachyarrhythmias, severe anaemia, respiratory failure, or severe hypotension/hypertension).
Hypertension
A chronic medical condition characterized by consistent elevation of systemic arterial blood pressure, clinically defined as a reading of 140/90mmHg or higher.
Mean Arterial Pressure (MAP)
The average pressure in the systemic arterial system throughout a complete cardiac cycle, representing tissue perfusion pressure.
Baroreceptors
Specialized stretch-sensitive mechanoreceptors located in the carotid sinus and aortic arch that become activated when arterial pressure or vascular wall stretch increases to regulate blood pressure.
Cardiac Output (CO)
The volume of blood pumped by the heart per minute, calculated using the formula: CO=HR×SV (Heart Rate multiplied by Stroke Volume).
Aldosterone
A mineralocorticoid hormone stimulated by Angiotensin II that acts on the kidneys to promote sodium and water reabsorption, thereby expanding intravascular blood volume and elevating blood pressure.
Antidiuretic Hormone (ADH)
A posterior pituitary hormone that increases blood pressure primarily by increasing renal water reabsorption in the collecting ducts.
Modifiable Risk Factors for ACS
Controllable factors contributing to atherosclerosis and coronary thrombosis, including cigarette smoking, physical inactivity, dyslipidaemia (elevated LDL and triglycerides), obesity/high BMI (visceral abdominal fat), diabetes mellitus, hypertension, and chronic psychosocial stress.
Non-Modifiable Risk Factors for ACS
Inherent patient characteristics increasing cardiovascular risk, including advancing age (80% of deaths occur in patients ≥65years), male sex (earlier onset, though female risk rises post-menopause), family history in first-degree blood relatives (<55years in men, <65years in women), and genetic markers.
High-Sensitivity Cardiac Troponin T (hs-cTnT)
The preferred cardiac biomarker for detecting myocardial necrosis; it rises within 2–3hours of injury, peaks at 12–48hours, and remains elevated for 4–14days (normal reference range: 0–14ng/L).
Creatine Kinase-MB (CK-MB)
A cardiac isoenzyme that elevates within 4–6hours of myocardial necrosis, peaks at approximately 24hours, and returns to baseline within 48–72hours; primarily useful for detecting early reinfarction.

Myocardial Infarction Investigation Findings
A sequential pathophysiological cascade where tissue necrosis triggers inflammation (↑CRP, ↑WBC), myocyte cell membrane disruption releases intracellular enzymes (troponins, CK-MB), and ischaemia disrupts electrical conduction causing ST deviations and pathological Q waves.
Pathological Q Wave
An ECG waveform deflection greater than 2 small boxes (>0.04seconds in duration or greater than 25% of R-wave amplitude) that signifies transmural myocardial necrosis or established scar.
T-Wave Tombstoning
An early, hyperacute ECG manifestation characterized by tall, peaked, symmetric T waves resulting from cellular hypoxia and localized potassium shifts during acute myocardial ischaemia.
Transmural Ischaemia
Ischaemia spanning the full thickness of the myocardial wall from endocardium to epicardium, characteristically causing ST-segment elevation on surface ECG leads.
Subendocardial Ischaemia
Ischaemic injury confined to the inner layer of the myocardium where tissue pressure is highest and perfusion lowest, typically manifesting on an ECG as ST-segment depression or T-wave inversion.

ECG Myocardial Damage Localization Chart
A diagnostic reference matching affected ventricular walls to ECG leads and coronary arteries: Anterior (V2–V4, LAD), Anterolateral (I, aVL, V3–V6, LAD/Circumflex), Septal (V1–V2, LAD), Inferior (II, III, aVF, RCA), Lateral (I, aVL, V5–V6, Circumflex), Posterior (V8–V9, RCA/Circumflex), and Right Ventricular (V4R–V6R, RCA).
Right Ventricular Infarction Signs
Clinical presentation resulting from backward right ventricular failure, characterized by jugular venous distension, hepatomegaly, systemic hypotension, and clear lung fields (dry chest).
Left Ventricular Infarction Signs
Clinical manifestations resulting from backward left ventricular failure, characterized by elevated pulmonary capillary wedge pressure, pulmonary oedema, dyspnoea, tachypnoea, hypoxia, and bilateral inspiratory crackles.
Diaphoresis in AMI
Profuse cold sweating without fever occurring during acute myocardial infarction due to intense activation of the sympathetic nervous system (SNS), considered an ominous red flag for STEMI.
MOAN Acronym
A traditional clinical mnemonic outlining initial pharmacological interventions for acute myocardial infarction: Morphine, Oxygen (only if SaO2<94%), Aspirin (300mg oral loading dose), and Nitrates (sublingual or IV GTN).
Aspirin (in ACS)
An antiplatelet agent that irreversibly inhibits cyclooxygenase-1 (COX-1), blocking thromboxane A2 synthesis; administered immediately as a 300mg chewed or dissolved loading dose (reducing 30-day mortality by 20%), followed by 100–150mg/day indefinitely.
Glyceryl Trinitrate (GTN)
A nitrate vasodilator converted to nitric oxide (NO) that dilates systemic veins to reduce ventricular preload and wall stress, and dilates coronary arteries to enhance myocardial blood supply (0.3–0.6mg sublingual tablet or 0.4–0.8mg spray every 5minutes, max 3 doses).
Morphine (in ACS)
An opioid analgesic administered at 2–2.5mg IV increments for persistent ischaemic chest pain that provides analgesia, anxiolysis, reduces sympathetic drive, and causes venodilation to decrease ventricular preload and myocardial oxygen demand.

Percutaneous Coronary Intervention (PCI)
A catheter-based coronary reperfusion technique using balloon angioplasty and bare-metal or drug-eluting stent deployment to mechanically restore lumen patency in an occluded culprit artery.
Primary PCI Timing Benchmarks
The preferred reperfusion therapy for STEMI if it can be performed within 90minutes of First Medical Contact (FMC) or Door-to-Balloon (DTB) time <60minutes; superior to fibrinolysis in reducing mortality, recurrent infarction, and stroke.

STEMI Reperfusion Strategy Pathways
An evidence-based decision tree dictating immediate primary PCI if door-in to door-out (DI-DO) and transfer to a PCI centre enables FMC-to-balloon time <90minutes; otherwise, immediate fibrinolytic therapy within 30minutes door-to-needle (DTN) time is indicated.

Tenecteplase (Metalyse)
A recombinant fibrin-specific tissue plasminogen activator (tPA) administered as a weight-tiered single IV bolus over 10 seconds: <60kg=30mg (6mL); 60–<70kg=35mg (7mL); 70–<80kg=40mg (8mL); 80–<90kg=45mg (9mL); ≥90kg=50mg (10mL). Doses are halved in patients aged ≥75years.
Absolute Contraindications to Fibrinolysis
Clinical factors precluding fibrinolytic administration due to catastrophic bleeding risks: prior intracranial haemorrhage at any time, ischaemic stroke within 6 months, known central nervous system neoplasm/vascular malformation, major surgery/parenchymal biopsy/significant trauma within 2 months, active internal bleeding or haemorrhagic diathesis, and suspected aortic dissection.
Rescue Percutaneous Coronary Intervention
Emergency mechanical coronary reperfusion performed following failed fibrinolytic therapy, defined objectively by ≤50% ST-segment resolution on a 12-lead ECG at 60–90minutes post-fibrinolysis or persistent haemodynamic instability.

Coronary Artery Bypass Graft (CABG)
A surgical revascularisation procedure utilizing harvested venous or arterial conduits to bypass coronary stenoses; recognized as the preferred revascularisation strategy over PCI in patients with diabetes mellitus and complex multi-vessel disease.
Post-Femoral Access PCI Nursing Orders
Specific vascular access protocols to prevent femoral pseudoaneurysm and haematoma: maintain strict supine bedrest (lay flat) for 4hours, sit at 30∘ for 6hours, perform lower-limb neurovascular observations hourly for 4hours then 4-hourly for 24hours, and inspect puncture site every 15minutes for 1 hour, hourly for 4hours, then 4-hourly for 24hours.
Dual Antiplatelet Therapy (DAPT)
The combination of aspirin (100–150mg/day) and a potent P2Y12 receptor inhibitor (ticagrelor 90mg BD, prasugrel 10mg daily, or clopidogrel 75mg daily) prescribed for 12 months after ACS to prevent stent thrombosis and secondary ischaemic events.
Ticagrelor
An oral, direct-acting, reversibly-binding P2Y12 platelet receptor antagonist administered as a 180mg loading dose followed by 90mg twice daily; preferred over clopidogrel across all ACS presentations regardless of revascularisation strategy.
Prasugrel
A potent thienopyridine P2Y12 inhibitor administered as a 60mg loading dose and 10mg daily maintenance for ACS patients undergoing PCI; contraindicated in patients with prior stroke/TIA, age ≥75years, or body weight <60kg.
Glycoprotein IIb/IIIa Inhibitors
Intravenous antiplatelet agents (e.g., abciximab, tirofiban, eptifibatide) that block the final common pathway of platelet aggregation by preventing fibrinogen cross-linking; indicated in combination with heparin during PCI in high-risk patients or for acute thrombotic complications.
Bivalirudin
A parenteral direct thrombin inhibitor (0.75mg/kg IV bolus followed by 1.75mg/kg/hr infusion) utilized as an alternative to heparin plus GP IIb/IIIa inhibitors during PCI in patients with high baseline bleeding risk.
TIMI Risk Score for NSTEACS
A 7-point clinical risk stratification score (incorporating age ≥65, ≥3 CAD risk factors, known CAD >50%, aspirin use in past 7 days, ≥2 angina episodes in 24 hours, ST deviation ≥0.5mm, and elevated biomarkers) predicting 14-day MACE risk.
GRACE Risk Score
A validated prognostic model (scoring 2 to 306) utilizing age, heart rate, systolic blood pressure, creatinine, Killip class, cardiac arrest at admission, ST deviation, and elevated enzymes to predict in-hospital and 6-month all-cause mortality in ACS.
CRUSADE Bleeding Score
A validated clinical score ranging from 0 to 96 points that quantifies the baseline probability of in-hospital major bleeding in NSTEACS to guide safe invasive and antithrombotic management.
ADAPT Accelerated Diagnostic Protocol
A 2-hour assessment protocol for emergency chest pain that identifies low-risk patients suitable for early discharge based on negative sensitive/highly-sensitive troponin at 0 and 2 hours, a TIMI score of 0 (or 0–1 in modified ADAPT), and normal serial ECGs.
Sgarbossa Criteria
ECG diagnostic rules for identifying acute myocardial infarction in the presence of Left Bundle Branch Block (LBBB): ST elevation ≥1mm concordant with QRS (5 points), ST depression ≥1mm in leads V1–V3 (3 points), and ST elevation ≥5mm discordant with QRS (2 points); a score ≥3 yields 98% specificity for MI.
Serum Potassium Target in AMI
Maintaining serum potassium concentrations tightly around 4.0mmol/L (normal reference range: 3.5–5.2mmol/L) to stabilize cardiac myocyte resting membrane potentials and minimize ventricular tachyarrhythmias.

Clinical Handover Standard Key Principles (NSW Health)
A standardized clinical communication framework encompassing six foundational principles: Leadership, Valuing Handover, Handover Participants, Handover Time, Handover Place (face-to-face at the bedside), and Handover Process utilizing structured communication tools like ISBAR.
ISBAR Communication Framework
A structured communication mnemonic utilized during clinical handover to ensure patient safety: Introduction (identify self, role, patient), Situation (immediate status/concern), Background (medical history, presentation), Assessment (current vital signs, clinical findings), and Recommendation (required actions, plan, timeframes).
Interactive ECG Online Video Series
A suite of three interactive multimedia modules ('The Heart in 3D', 'Electrical impulse', and 'Contraction') accessed with the password 'ECG' to reinforce foundational cardiac electrophysiology, depolarization waveforms, and chamber contraction mechanics.
Cardiac Rehabilitation
A comprehensive secondary prevention service comprising structured exercise training, lifestyle risk-factor counseling (smoking cessation, diet), and education that reduces 12-month cardiovascular mortality and hospital admissions post-ACS.